Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET-Mutant Medullary Thyroid Cancer and RET Fusion-Positive Thyroid Cancer from LIBRETTO-001 at the 88th Annual Meeting of the American Thyroid Association
October 06, 2018 09:05 ET
|
Loxo Oncology, Inc.
- 16/17 (94%) Responding RET-Mutant Medullary Thyroid Cancer Patients Remain on Therapy, With Median Follow-Up of 8.4 Months - - 7/7 (100%) Responding RET Fusion-Positive Thyroid Cancer Patients...
Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer from LIBRETTO-001 at the IASLC 19th World Conference on Lung Cancer
September 25, 2018 16:20 ET
|
Loxo Oncology, Inc.
- 25/26 (96%) Responding Patients Remain on Therapy, With Median Follow-Up of 9.5 Months - STAMFORD, Conn., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO), a...
Loxo Oncology Announces Accepted Abstracts at the 88th Annual Meeting of the American Thyroid Association
September 18, 2018 06:45 ET
|
Loxo Oncology, Inc.
STAMFORD, Conn., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined...
Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292
September 05, 2018 06:45 ET
|
Loxo Oncology, Inc.
STAMFORD, Conn., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined...
Loxo Oncology to Present at Upcoming Investor Conferences
August 29, 2018 06:45 ET
|
Loxo Oncology, Inc.
STAMFORD, Conn., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers,...
Loxo Oncology Announces Submission of European Marketing Authorization Application for Larotrectinib
August 27, 2018 02:30 ET
|
Loxo Oncology, Inc.
STAMFORD, Conn., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers,...
Loxo Oncology Announces Accepted Abstracts at the IASLC 19th World Conference on Lung Cancer
August 10, 2018 16:30 ET
|
Loxo Oncology, Inc.
STAMFORD, Conn., Aug. 10, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers,...
Loxo Oncology Reports Second Quarter 2018 Financial Results
August 09, 2018 06:45 ET
|
Loxo Oncology, Inc.
- LOXO-292 New Drug Application (NDA) Submission to FDA Expected in Late 2019 - - Updated Larotrectinib Duration of Response Data to be Reported at ESMO - - Larotrectinib NDA PDUFA date is November...
Loxo Oncology to Announce Second Quarter 2018 Financial Results
August 02, 2018 06:45 ET
|
Loxo Oncology, Inc.
STAMFORD, Conn., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers,...
Loxo Oncology Announces Positive Interim Clinical Data from LOXO-292 Dose Escalation Trial in RET-Altered Cancers Presented at the American Society of Clinical Oncology Annual Meeting
June 02, 2018 09:00 ET
|
Loxo Oncology, Inc.
– 77% Overall Response Rate in RET Fusion Cancers and 45% Overall Response Rate in RET Mutated Medullary Thyroid Cancer (MTC) – – Activity Observed Independent of RET Alteration, Tumor Type...